BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28
• 31

• Press Releases

  FDA Roundup: March 7, 2025

  March 10, 2025

   · 

  2 min read
• Press Releases

  Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 7, 2025

  March 10, 2025

   · 

  1 min read
• Press Releases

  Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis

  March 10, 2025

   · 

  16 min read
• Press Releases

  Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

  March 10, 2025

   · 

  15 min read
• Press Releases

  Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

  March 10, 2025

   · 

  16 min read
• Press Releases

  Lilly’s baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

  March 10, 2025

   · 

  19 min read
• Press Releases

  U.S. FDA approves Celltrion’s OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®

  March 10, 2025

   · 

  10 min read
• Press Releases

  MAY HEALTH APPOINTS SEASONED MEDTECH EXECUTIVE, COLBY HOLTSHOUSE, AS PRESIDENT AND CEO

  March 10, 2025

   · 

  6 min read
• Press Releases

  AAVantgarde announces 2 presentations at ARVO 2025 annual meeting: LUCE-1 clinical trial data from Usher 1B program & NHP GLP data from Stargardt disease program

  March 10, 2025

   · 

  2 min read
• Press Releases

  I-Mab Announces Accelerated Givastomig Phase 1b Study Progress

  March 10, 2025

   · 

  5 min read